How Much Does a Breztri Inhaler Cost?

Published on July 27, 2025 | Prices Last Reviewed for Freshness: December 2025
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer.

Breztri Aerosphere is a brand‑name COPD prescription combining an inhaled corticosteroid, a long‑acting beta agonist, and a muscarinic antagonist, sold only as a single device—no generic exists. The recent buzz ties to cost, not chemistry: patients try to find an affordable way to buy it, compare each pharmacy price, and stack a coupon or discount to cut the payment. AstraZeneca’s marketing plus new policy moves turned a niche deal into national conversation.

People who benefit are adults with moderate to severe COPD who need triple therapy in one inhaler for adherence and convenience. For them, a lower price or capped cost keeps therapy continuous and outcomes stable.

Caregivers chase the lowest payment path, pharmacists juggle formularies to keep fills affordable, and clinicians must know when a patient hits a wall on copay. The hype rises because a brand that once averaged $860–$908 cash now advertises $0–$35 pathways, creating a sharp compare point in every clinic visit.

Article Highlights

• $400 low cash fill vs. $860–$877 common retail tag.
• Insured sample: $664 list, $23 off, $641 final payment.
• $29 per dose math helps compare Breztri to rivals.
• Trelegy users can hit $35/month with the right coupon; Breztri rarely dips that low.
• Tier drops and 90‑day orders create fast savings.
• No generic exists; watch the formulary each plan year.
• Assistance programs close gaps for Medicare and uninsured patients.

How Much Does a Breztri Inhaler Cost?

We found uninsured cash tags clustering between $400 (small 5.8–5.9 g canister) and $860–$877 for a standard 30‑day 10.7 g fill. That span reflects each pharmacy price, wholesaler contracts, and dispensing fees. A 2022 retail anchor sat at $664; today’s sticker shows a ~30% rise. The price per dose lands near $29 when you divide total cost by actuated sprays. Those figures help patients compare a “cheap” refill claim to reality and decide if a 90‑day order makes sense.

Insurance flips the script. A commercial plan quoted $664 list, applied a $23 discount, and left an insured payment of $641. Medicare Part D data show broad coverage, yet tiers and deductibles set the real copay. Some cards cap triple‑therapy inhalers at flat rates, others push members into higher payment brackets until the donut hole closes. Monthly vs. quarterly fills also shape cash flow; three‑month supplies often trim the per‑month cost and one copay charge instead of three.

Real‑world Pricing Data

SingleCare reports uninsured buyers see an average retail cost near $860 per 30‑day 10.7 g inhaler unless they apply a coupon. GoodRx logs an average price of $785.95, with a $656.20 “as low as” deal using its card. That difference illustrates how a discount service can beat one pharmacy but lose to another, so always compare before you buy.

Medical News Today and Healthline place the 5.8–5.9 g canister around $400 cash and the larger 10.7 g size around $700 (some sources say “double”), aligning with GoodRx’s Medicare view that 87% of plans cover Breztri but still vary on copay. That smaller fill lowers the sticker but may raise annual payment if you refill more often.

We also saw a legacy list price of $664 in 2022, with a $23 manufacturer discount cutting one insured bill to $641—a snapshot that many plans still reference. Those anchors matter when a cashier quotes $908.40 or $717 and calls it “standard.” (give or take a few dollars) Check dose, grams, and store fee before accepting the prcie—price on screen.

Also check out our articles on the cost of other inhalers like Airsupra and Albuterol, or allergy testing.

Coupon and Assistance Programs

The BREZTRI Zero Pay card advertises $0–$35/month for eligible commercially insured patients, even when the plan doesn’t actively cover the drug. Enrollment runs through the brand site; limits and maximum benefit caps apply. AstraZeneca’s support pages confirm a full‑year path “as little as $0.”

For Medicare users or uninsured low‑income patients, the AZ&Me program supplies medication at no cost if criteria are met. AAFA and AstraZeneca list it as a key lifeline when standard coupon cards exclude government plans. Pair that with nonprofit grants to drop actual payment near zero.

GoodRx, SingleCare, Optum Perks, and similar cards shave retail price—for example, $656 on a $785.95 average tag—yet cannot be combined with insurance. Patients must order cash and submit receipts or choose whichever deal nets the lowest end cost.

Scenario matrix

We built a quick matrix to compare scenarios. Numbers use published list prices, known discount amounts, and typical copay structures. Use it to find your lane and plan the payment cadence.

These figures show how a strategic coupon or formulary tier drop erases hundreds from the bill.

The uninsured buyer’s best path is often a cash discount card; the insured buyer aims at a manufacturer deal plus a lower tier. Medicare users ride the Part D phases until the $2,000 cap zeroes further payment.

Real‑life Cost Examples

Case 1: An uninsured patient pays the full retail price at a local chain—$860 at Store A, $877 online at Store B—no coupon, no deal. Their out‑of‑pocket cost hits $860–$877 every month until income qualifies for a patient assistance program.

Case 2: A privately insured user faces tier‑3 placement. Their plan lists $664, subtracts a $23 card, and sets a copay of $641. Another plan pegs a percentage coinsurance, turning Breztri into a sliding payment. Switching pharmacies trimmed $18 off the final price after a discount network applied.

Case 3: A patient leverages AstraZeneca’s manufacturer coupon and gets the first fill for $0–$35, then pays up to $200 per month after limits. A Medicare enrollee taps a foundation grant to drop the cost to $50 monthly. Mini‑case: One user moved from Trelegy ($500–$600) to Breztri ($860–$877) and saw a net expense jump, but symptom control justified the switch.

Cost Breakdown

We found four consistent buckets: base pharmacy price, insurance share, patient copay/payment, and ancillary fees. Base tags show $400, $664, or $860–$877 depending on strength and supply. Plans then apply formularies: tier 3 or 4 raises the copay, tier 2 lowers it. Coinsurance percentages turn the wholesale acquisition cost into variable math each month.

Extra charges show up as dispensing fees, delivery charges, or refill synchronization services. Mail‑order sometimes adds shipping; others waive it to gain volume. The device itself—Breztri Aerosphere—comes bundled, so there is no separate hardware sale. Still, some clinics bill inhaler training visits, adding a small payment to the first fill. Track all of it to see where to save and where a coupon actually bites.

Factors Influencing the Cost

We found drug formulary tiering drives the biggest swings. A move from tier 4 to tier 3 drops the copay instantly. Plans judge Breztri against substitutes like Symbicort or Trelegy, then assign a payment level. Manufacturer pricing and wholesale markups keep the list price high while rebates flow behind the scenes. No generic exists yet, so patients cannot simply swap to a low‑cost copy.

Regional pharmacy networks and negotiating power change the shelf price. Independent stores sometimes beat national chains with a discount club. Market price shifts since 2022 show a ~30% rise, matching broader drug inflation. Policy updates—like Medicare’s $35 insulin cap—hint at future respiratory caps, but none apply widely to Breztri today. Stay alert for formulary re‑reviews each January; that single policy edit can spike or cut what you pay.

Market and Policy Changes

We found AstraZeneca capped out‑of‑pocket costs at $35/month for its U.S. inhaled respiratory portfolio starting June 1, 2024, covering uninsured and commercially insured patients who meet program rules. That single policy reframes “cheap” and “best deal” conversations, since a fixed price beats chasing the lowest pharmacy tag each month.

Medicare Part D introduces a separate lever: a $2,000 annual out‑of‑pocket cap beginning in 2025 under the Inflation Reduction Act. Long‑term Breztri users will stop paying once that ceiling is hit, shifting the yearly payment curve and making high‑tier drugs more affordable across the calendar. Plans can also offer a monthly spread program so members pay over the year instead of in a single spike.

This broader policy backdrop arrives amid scrutiny of inhaler prices and corporate PR campaigns. Boehringer Ingelheim and GSK joined the $35 cap wave, signaling a market push to save face and patients money. The interplay between voluntary caps, federal limits, and state assistance creates multiple discount layers that patients can order in tandem.

Retail inflation since 2022 shows a ~30% rise in sticker cost

SingleCare and Healthline peg the 2022 price near $664, while 2024–2025 cash quotes circle $860–$908. That is roughly a 30% jump in retail cost, mirroring broader drug inflation and no generic competition.

Medical News Today repeats the $400 small canister and “double” figure for the larger size, aligning with the upward drift. The climb widens the gap between those who save with a coupon and those who pay list.

Policy levers blunt but don’t erase inflation. The $35 cap and $2,000 Part D limit shield patients, yet plans and taxpayers absorb part of that payment shift. That cost transfer keeps Breztri’s market price high even as point‑of‑sale bills drop.

Formularies and tiering structures

Healthline explains that the tier a drug sits on sets the copay: Tier 3 means higher payment, Tier 4 higher still. GoodRx confirms Breztri often lands on Tier 3 for Medicare PDPs. Coinsurance models tie the patient cost to a percentage of price, creating large swings until caps kick in.

A shift from Tier 4 to Tier 3 immediately drops the member’s cost, often more than any single coupon. Patient advocates urge constant formulary checks each January; a silent tier move can add $100+ to one fill.

Coinsurance plans complicate “best deal” math: a discount card cannot stack with insurance, so patients must compare cash vs. plan each month. One misread refill can erase savings you fought to find.

Alternative Products or Services

We compared triple and dual therapies to highlight cost comparison threads. Breztri Aerosphere lands at $860–$877 uninsured. Trelegy Ellipta lists around $500–$600, and eligible patients see $35/month caps under GSK’s program. Stiolto Respimat tracks near $400–$500 without insurance coverage.

A generic albuterol rescue inhaler costs $20–$50, but it is not comparable therapy. Each option carries different discount programs, so always compare, buy, and order with that in mind.

Table 1. COPD Inhaler Price Comparison (Uninsured Monthly Estimate)

When we priced two mail‑order options, Trelegy’s auto‑ship shaved $12 per month; Breztri’s did not. That delta shows why a quick compare yields real savings.

Ways to Spend Less

We found five levers: manufacturer coupon, independent pharmacy shopping, 90‑day order, patient assistance enrollment, and switching to a covered alternative. Start with AstraZeneca’s card, then layer a SingleCare or GoodRx discount if your plan allows. Ask for a 90‑day supply to cut two copays. Medicare or Medicaid users should confirm formulary placement and seek foundation grants early in the year before funds dry up.

Price‑match policies help. Some chains honor a competitor’s deal if you show proof. Mail‑order often reduces the per‑fill payment by spreading overhead. If your plan blocks Breztri or slots it high, appeal with clinical notes or request a tier exception. In one test, a tier drop saved $138 per month instantly. Keep receipts; some assistance programs reimburse retroactively.

Expert Insights 

Erin Fox, PharmD (University of Utah Drug Information Service) says, “Tier shifts on a drug formulary change the copay faster than any shiny coupon.”

Tori Marsh, MPH (Director of Research, SingleCare) notes, “Comparing three pharmacy quotes often finds a $40–$60 swing on the same inhaler—easy savings for a five‑minute search.”

David Au, MD (Pulmonologist, VA Puget Sound) adds, “Triple therapy helps adherence, but a $800+ price tag breaks adherence—design a payment plan before the first fill.”

Leslie Bailey, RPh (Community Pharmacist): “Ask for a 90‑day script; one copay beats three, and delivery trims hidden fees.”

Answers to Common Questions

Does Breztri qualify for Medicare “Extra Help” discounts?

Yes, many beneficiaries with Extra Help pay reduced copays; apply through Social Security and pair it with a manufacturer coupon if allowed.

Can I split a 10.7 g inhaler into two months to cut the price?

Dosing schedules set usage. Stretching doses risks control loss and does not lower the billed cost since the pharmacy charges per unit, not per puff.

Will a Canadian pharmacy sell Breztri cheaper legally?

Import rules restrict personal order volumes. Some licensed services ship for $500–$600, but legal and safety steps add friction.

Does a mail‑order pharmacy always save money?

No. Some plans apply the same copay. Still compare; one network saved $18 for a user, another saved $0.

Are hospital outpatient pharmacies cheaper for staff or patients?

Employee discount programs exist, but general patients often see standard prices. Always compare before you buy.